Progress and experience about advanced pancreatic cancer at the Johns Hopkins
Abstract：Current therapies for pancreatic cancer have limited effects. Precision medicine has shown great potential for clinical applications,include new pancreatic cancer classification based on genomics and transcriptomics,through a minimally invasive "liquid biopsy" to detect circulating tumor cells,circulating cell-free DNA,and exosomes,which are permited to monitor of the clonal evolution of individual pancreatic cancer during the course of treatment and disease progression. Various strategies are being tested in clinical trials in Johns Hopkins, examining genes that are involved in the metabolism of chemotherapeutic agents help to select a more accurate,higher response rate of chemotherapy. Based on tumor genome and transcriptome,the landscape of the pancreatic ductal adenocarcinoma genome is notable,study of mutant genes will be helpful in selecting the best treatment. Treatment selection based on host immune response,designed based on whole-exome sequencing of mutated genes,will facilitate further tailoring of vaccine therapies for individual patients,at present,the combination of pancreatic cancer vaccine and chemotherapy drugs has achieved some positive results,and further studies are being carried out.
Keywords：pancreatic carcinomaprecision medicinechemotherapyimmunotherapygenomics
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 755-760 )